ASC23

ASC23 is an investigational therapeutic candidate being developed by Ascletis Pharmaceuticals for the treatment of psoriasis and other autoimmune diseases. According to company pipeline information, the drug is designed as a bispecific antibody or an antibody-drug conjugate (ADC) targeting interleukin-17 (IL-17). IL-17 is a pro-inflammatory cytokine that plays a central role in the pathogenesis of various autoimmune conditions by promoting tissue inflammation and neutrophil recruitment. By targeting IL-17, ASC23 aims to inhibit the inflammatory cascade associated with chronic plaque psoriasis and related disorders. The use of a bispecific or ADC approach suggests a strategy to enhance the potency or selectivity of IL-17 inhibition compared to traditional monoclonal antibodies.